CETP and hypoalphalipoproteinemia: Furthermore, the CETP inhibitor dalcetrapib decreased circulating levels of oxidised LDL in familial hypoalphalipoproteinemia [47], whereas CETP inhibition in vitro by a monoclonal antibody renders LDL more resistant to oxidation [48], observations which are consistent with the absence of a deficiency in the HDL-mediated protection of LDL from oxidation in vivo.